Jefferies reiterates Genentech at buy

Genentech, Inc. was reiterated by Jefferies & Co., Inc. analyst Adam Walsh at a buy. According to Jefferies' survey, Avastin has largely penetrated the metastatic colorectal cancer (mCRC) market. The survey of 20 oncologists evaluated the future mCRC landscape, including Avastin, Erbitux and Panitumumab. In addition, the Food and Drug Administration has approved Avastin in combination with intravenous 5-fluorouracil (5-FU) based chemotherapy for second-line mCRC. Shares of the South San Francisco, Calif.-based biotherapeutic company were up 70 cents, or 0.91%, at $77.63 on volume of 2,286,600 shares versus the three-month running average of 3,547,380 shares. (NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.